Table 3 Clinical characteristics of the five ovarian cancer patients with stable disease for over 200 days.
Baseline characteristics | 6MP study treatment details | ||||||
|---|---|---|---|---|---|---|---|
Patient ID | Mutated BRCA gene | Prior PARP treatment | Volume of disease | TPMT status | 6MP starting dose (mg) | Mean daily 6MP dose intensity (mg) | No. of days on trial |
Patient 1 | 1 | Yes | Visceral | High/high | 140 | 98.1 | 303 |
Patient 2 | 1 | No | Visceral | High/high | 130 | 93.2 | 287 |
Patient 3 | 2 | Yes | Visceral | High/high | 120 | 58.7 | 260 |
Patient 4 | 1 | Yes | Nodal only | High/high | 110 | 98.3 | 455 |
Patient 5 | 2 | No | Visceral | High/high | 100 | 67.6 | 252* |
